Search / 37 results found

from
to
  • Updated

CAMBRIDGE, Mass., Nov. 16, 2021 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM). The data is being presented in a poster session at the Society for NeuroOncology's (SNO) 2021 Annual Meeting, taking place from November 18-21, 2021 in Boston.

  • Updated

BOSTON, Nov. 12, 2021 /PRNewswire/ -- PathAI, a global provider of AI-powered technology applied to pathology announced that results from a recent exploratory biomarker analysis on digitized slides to apply AI-predicted CD8 topology assessment of patients with advanced melanoma will be presented at the annual Meeting of Society for Immunotherapy of Cancer, November 10-14 2021.

  • Updated

MARLBOROUGH, Mass., Nov. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new study data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. The data from this study in an in vivo hepatocarcinoma model shows that PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response.

  • Updated

MARLBOROUGH, Mass., Nov. 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

  • Updated

CAMBRIDGE, Ma., Nov. 9, 2021 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma (rGBM). The data is being presented in the poster session at the Society for Immunotherapy of Cancer's (SITC) 2021 Annual Meeting, taking place from November 10-14, 2021.

  • Updated

CAMBRIDGE, Mass., Nov. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event will be hosted live in Washington, D.C. and virtually from November 10-14, 2021.

  • Updated

CAMBRIDGE, Mass., Nov. 8, 2021 /PRNewswire/ -- ATP, a leader in life sciences venture capital, today announced the launch of Marengo Therapeutics, Inc. to develop novel antibodies that target Vβ T cell receptor (TCR) variants, selectively boosting anti-tumor T cells and promoting long-term protection against cancer. $80 million in launch financing from ATP will help advance Marengo's proprietary Selective T Cell Activation Repertoire (STAR) platform and progress the company's lead candidate into the clinic in 2022.

  • Updated

CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ --Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application to evaluate THE-630, the company's lead development candidate, in patients with gastrointestinal stromal tumors (GIST). THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy.

  • Updated

HADLEY, Mass., Oct. 21, 2021 /PRNewswire/ -- A paper published today in the journal Nature Communications (https://www.nature.com/articles/s41467-021-26367-9) describes using a bacterial foe, salmonella, to treat cancer. Ernest Pharmaceuticals and the Forbes Lab at UMass/Amherst developed a salmonella-based cancer therapy that selectively invades cancer cells, then produces and delivers a cancer drug to kill the tumor. The paper describes research that shows that this therapy could become a powerful weapon in the war against cancer.